Causes of Seronegative Autonomic Ganglionopathy
Seronegative autoimmune autonomic ganglionopathy represents a distinct clinical entity from seropositive AAG, with causes including immune checkpoint inhibitor therapy, post-infectious immune-mediated mechanisms, and idiopathic autoimmune processes targeting autonomic ganglia without detectable ganglionic acetylcholine receptor antibodies.
Primary Etiologic Categories
Immune Checkpoint Inhibitor-Induced AAG
The most clearly documented cause of seronegative AAG in recent literature is dual immune checkpoint inhibitor therapy (ipilimumab plus nivolumab) used in cancer treatment, particularly metastatic melanoma 1. This represents an immune-related adverse event where the immune system attacks autonomic ganglia despite negative gAChR antibody testing. Single-agent checkpoint inhibitors can also trigger this condition 2.
Post-Infectious/Immune-Mediated Mechanisms
While the evidence primarily discusses seropositive AAG in the context of infections, seronegative cases likely share similar triggering mechanisms but lack the specific antibody response. The pathophysiology involves:
- Aberrant immune responses following infections that damage autonomic ganglia
- Molecular mimicry mechanisms (similar to those described in Guillain-Barré syndrome) 3
- Cross-reactive immune responses targeting autonomic nervous system components
Paraneoplastic Etiology
Small cell lung cancer (SCLC) can trigger seronegative AAG as part of paraneoplastic dysautonomia 4. While the guideline emphasizes that antibodies against neuronal acetylcholine receptors are "pathogenic and diagnostic," clinical cases demonstrate that seronegative variants exist with similar clinical presentations 5, 6.
Key Distinguishing Features from Seropositive AAG
Clinical Presentation Differences
Seronegative AAG shows distinct characteristics 5:
- Predominant sympathetic failure (rather than mixed cholinergic/sympathetic)
- Prominent sensory symptoms and pain (often severe in 50% of cases)
- Absence of specific pupillary findings typical of seropositive AAG (no premature pupillary redilation)
- More frequent severe sensory neuropathy component
Autonomic Testing Patterns
- Cardiovascular autonomic testing reveals poor sympathetic nervous system responses 1
- Diffuse colonic hypomotility and gastrointestinal dysfunction 6
- Orthostatic hypotension refractory to standard fluid resuscitation
Associated Conditions and Risk Factors
Cancer Immunotherapy Context
- Dual checkpoint inhibition carries higher risk than monotherapy 1
- Can recur with re-challenge of combination therapy
- May be manageable with continued single-agent therapy after initial resolution
Systemic Autoimmune Processes
The condition may occur in the context of:
- Other autoimmune neuropathies (sensorimotor peripheral neuropathy) 6
- Systemic immune dysregulation without identifiable antibodies
- Post-viral syndromes (though less well-documented than in seropositive cases)
Clinical Pitfalls
Critical distinction: Do not assume absence of gAChR antibodies rules out autoimmune autonomic ganglionopathy. Seronegative AAG is a separate disease entity requiring different treatment 5. The seronegative form responds poorly to antibody-targeted therapies (plasma exchange, IVIG, rituximab) but shows better response to corticosteroids 5, 6.
Diagnostic challenge: The condition may present initially with isolated gastrointestinal symptoms (severe constipation) before full autonomic failure becomes apparent, leading to delayed diagnosis (up to 10 months in documented cases) 6.
Testing limitations: Standard gAChR antibody testing may be negative, but this does not exclude the diagnosis when clinical presentation and autonomic testing support autoimmune autonomic failure 5, 7.